Is BNTX or LEGN more profitable?

Legend Biotech has a net margin of -21.98% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Legend Biotech -21.98% -24.92% -14.87%

Does the media favor BNTX or LEGN?

In the previous week, Legend Biotech had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Legend Biotech and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.07 beat Legend Biotech's score of 0.14 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LEGN or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Roivant Sciences and 6 mentions for Legend Biotech. Roivant Sciences' average media sentiment score of 1.51 beat Legend Biotech's score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, LEGN or INSM?

Legend Biotech has higher revenue and earnings than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.03B 5.30 -$296.80M -$0.68 N/A Insmed $606.42M 35.25 -$1.28B -$5.75 N/A

Is LEGN or INSM more profitable?

Legend Biotech has a net margin of -21.98% compared to Insmed's net margin of -144.44%. Legend Biotech's return on equity of -24.92% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Insmed -144.44% -130.11% -51.57%

Does the media favor LEGN or INSM?

In the previous week, Insmed had 9 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Insmed and 6 mentions for Legend Biotech. Insmed's average media sentiment score of 1.45 beat Legend Biotech's score of 0.14 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 13 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LEGN or MRNA more profitable?

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Moderna -143.55% -26.64% -19.32%

Does the media favor LEGN or MRNA?

In the previous week, Moderna had 44 more articles in the media than Legend Biotech. MarketBeat recorded 50 mentions for Moderna and 6 mentions for Legend Biotech. Moderna's average media sentiment score of 0.44 beat Legend Biotech's score of 0.14 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 23 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 12 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LEGN or VTRS more profitable?

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Viatris -2.04% 19.04% 7.62%

Does the media favor LEGN or VTRS?

In the previous week, Legend Biotech had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.47 beat Legend Biotech's score of 0.14 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Legend Biotech (LEGN) Competitors

$29.34 +1.41 (+5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$29.29 -0.05 (-0.17%)

As of 07:48 PM Eastern

Compare

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

Should you buy Legend Biotech stock or one of its competitors? MarketBeat compares Legend Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Legend Biotech include BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Legend Biotech compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

BioNTech presently has a consensus price target of $129.56, suggesting a potential upside of 43.66%. Legend Biotech has a consensus price target of $60.23, suggesting a potential upside of 105.29%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioNTech has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Legend Biotech had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Legend Biotech and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.07 beat Legend Biotech's score of 0.14 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech has lower revenue, but higher earnings than BioNTech. Legend Biotech is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.03	-$1.29B	-$5.88	N/A
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A

Legend Biotech has a net margin of -21.98% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

BioNTech beats Legend Biotech on 11 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Roivant Sciences?

Legend Biotech (NASDAQ:LEGN) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Legend Biotech has a net margin of -21.98% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, Roivant Sciences had 4 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for Roivant Sciences and 6 mentions for Legend Biotech. Roivant Sciences' average media sentiment score of 1.51 beat Legend Biotech's score of 0.14 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Legend Biotech currently has a consensus target price of $60.23, indicating a potential upside of 105.29%. Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 7.49%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Legend Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
Roivant Sciences	$8.26M	2,721.21	-$299.77M	-$0.60	N/A

Summary

Legend Biotech and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Insmed?

Legend Biotech (NASDAQ:LEGN) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Legend Biotech has a net margin of -21.98% compared to Insmed's net margin of -144.44%. Legend Biotech's return on equity of -24.92% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Insmed	-144.44%	-130.11%	-51.57%

Legend Biotech has higher revenue and earnings than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
Insmed	$606.42M	35.25	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 9 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Insmed and 6 mentions for Legend Biotech. Insmed's average media sentiment score of 1.45 beat Legend Biotech's score of 0.14 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Legend Biotech presently has a consensus target price of $60.23, suggesting a potential upside of 105.29%. Insmed has a consensus target price of $211.86, suggesting a potential upside of 114.85%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Insmed beats Legend Biotech on 10 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Moderna?

Legend Biotech (NASDAQ:LEGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Legend Biotech has higher earnings, but lower revenue than Moderna. Legend Biotech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
Moderna	$1.94B	12.11	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 44 more articles in the media than Legend Biotech. MarketBeat recorded 50 mentions for Moderna and 6 mentions for Legend Biotech. Moderna's average media sentiment score of 0.44 beat Legend Biotech's score of 0.14 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	23 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Legend Biotech presently has a consensus price target of $60.23, suggesting a potential upside of 105.29%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 38.33%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Moderna	-143.55%	-26.64%	-19.32%

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Legend Biotech and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Viatris?

Legend Biotech (NASDAQ:LEGN) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Viatris	-2.04%	19.04%	7.62%

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Legend Biotech has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.30	-$296.80M	-$0.68	N/A
Viatris	$14.30B	1.25	-$3.51B	-$0.26	N/A

In the previous week, Legend Biotech had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.47 beat Legend Biotech's score of 0.14 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech currently has a consensus price target of $60.23, indicating a potential upside of 105.29%. Viatris has a consensus price target of $17.50, indicating a potential upside of 13.78%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Legend Biotech is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Viatris beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.45B	$3.43B	$6.42B	$12.38B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-43.15	19.86	24.82	24.35
Price / Sales	5.30	330.22	571.82	128.89
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	5.40	8.34	10.85	6.58
Net Income	-$296.80M	$23.80M	$3.56B	$336.75M
7 Day Performance	-17.31%	3.63%	0.70%	-0.49%
1 Month Performance	-0.10%	1.77%	0.29%	1.56%
1 Year Performance	-13.71%	58.60%	30.68%	33.78%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	4.3908 of 5 stars	$29.34 +5.0%	$60.23 +105.3%	-17.9%	$5.45B	$1.03B	N/A	2,965
BNTX BioNTech	4.5513 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-14.7%	$22.90B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0901 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+174.5%	$21.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.5017 of 5 stars	$97.46 -0.4%	$212.50 +118.0%	-6.8%	$21.21B	$606.42M	N/A	1,664	Positive News
MRNA Moderna	1.2371 of 5 stars	$52.13 +4.4%	$36.60 -29.8%	+146.9%	$19.80B	$1.94B	N/A	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

How does Legend Biotech compare to BioNTech?

Summary

How does Legend Biotech compare to Roivant Sciences?

Summary

How does Legend Biotech compare to Insmed?

Summary

How does Legend Biotech compare to Moderna?

Summary

How does Legend Biotech compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BNTX, ROIV, INSM, MRNA, and VTRS

How does Legend Biotech compare to BioNTech?

Do analysts prefer BNTX or LEGN?

Which has more volatility and risk, BNTX or LEGN?

Do institutionals & insiders hold more shares of BNTX or LEGN?

Does the media favor BNTX or LEGN?

Which has preferable earnings and valuation, BNTX or LEGN?

Is BNTX or LEGN more profitable?

Summary

How does Legend Biotech compare to Roivant Sciences?

Is LEGN or ROIV more profitable?

Do insiders and institutionals have more ownership in LEGN or ROIV?

Which has more volatility and risk, LEGN or ROIV?

Does the media refer more to LEGN or ROIV?

Do analysts prefer LEGN or ROIV?

Which has stronger valuation and earnings, LEGN or ROIV?

Summary

How does Legend Biotech compare to Insmed?

Is LEGN or INSM more profitable?

Which has higher earnings and valuation, LEGN or INSM?

Does the media favor LEGN or INSM?

Which has more risk and volatility, LEGN or INSM?

Do analysts recommend LEGN or INSM?

Do insiders & institutionals have more ownership in LEGN or INSM?

Summary

How does Legend Biotech compare to Moderna?

Which has stronger valuation and earnings, LEGN or MRNA?

Does the media favor LEGN or MRNA?

Which has more volatility & risk, LEGN or MRNA?

Do analysts rate LEGN or MRNA?

Is LEGN or MRNA more profitable?

Do institutionals and insiders have more ownership in LEGN or MRNA?

Summary

How does Legend Biotech compare to Viatris?

Is LEGN or VTRS more profitable?

Which has more volatility and risk, LEGN or VTRS?

Do institutionals & insiders believe in LEGN or VTRS?

Which has higher valuation and earnings, LEGN or VTRS?

Does the media favor LEGN or VTRS?

Do analysts rate LEGN or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools